Veracyte (VCYT) has released an update to notify the public and investors about its asset transaction finalization.
Veracyte, Inc. completed its acquisition of C2i Genomics for $70.0 million with additional future performance-based payments up to $25.0 million. The deal involves a combination of cash, escrow funds for indemnification, and shares of Veracyte stock, with a special provision for non-accredited investors. Veracyte will also register the shares for resale and has obtained a waiver to provide only selected financial statements for C2i Genomics, which will be disclosed in an upcoming report.
For further insights into VCYT financials, check out TipRanks’ Financials page.
For a comprehensive understanding of the announcement, you can read the full document here.
